NAV

Laropiprant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Laropiprant
DrugBank Accession Number
DB11629
Background

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 435.89
Monoisotopic: 435.0707351
Chemical Formula
C21H19ClFNO4S
Synonyms
  • Laropiprant
External IDs
  • MK-0524
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PELZONTLaropiprant (20 MG) + Niacin (1000 MG)Tablet, extended releaseOralOrganon Pharma (Uk) Limited2014-07-082022-10-06Italy flag
PELZONTLaropiprant (20 MG) + Niacin (1000 MG)Tablet, extended releaseOralOrganon Pharma (Uk) Limited2014-07-082022-10-06Italy flag
PELZONTLaropiprant (20 MG) + Niacin (1000 MG)Tablet, extended releaseOralOrganon Pharma (Uk) Limited2014-07-082022-10-06Italy flag
PELZONTLaropiprant (20 MG) + Niacin (1000 MG)Tablet, extended releaseOralOrganon Pharma (Uk) Limited2014-07-082022-10-06Italy flag
PELZONTLaropiprant (20 MG) + Niacin (1000 MG)Tablet, extended releaseOralOrganon Pharma (Uk) Limited2014-07-082022-10-06Italy flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolyl carboxylic acids and derivatives
Direct Parent
Indolyl carboxylic acids and derivatives
Alternative Parents
3-alkylindoles / N-alkylindoles / Chlorobenzenes / Substituted pyrroles / Aryl chlorides / Aryl fluorides / Sulfones / Heteroaromatic compounds / Azacyclic compounds / Carboxylic acids
show 8 more
Substituents
3-alkylindole / Aromatic heteropolycyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
G7N11T8O78
CAS number
571170-77-9
InChI Key
NXFFJDQHYLNEJK-CYBMUJFWSA-N
InChI
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
IUPAC Name
2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid
SMILES
CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1

References

General References
Not Available
ChemSpider
8043333
BindingDB
50205275
ChEBI
135942
ChEMBL
CHEMBL426559
ZINC
ZINC000003961849
PharmGKB
PA166129564
Wikipedia
Laropiprant

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedPreventionDyslipidemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentHigh Cholesterol2
4CompletedTreatmentPolycystic Ovarian Syndrome (PCOS)1
4TerminatedNot AvailableDyslipidemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, extended releaseOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00428 mg/mLALOGPS
logP3.58ALOGPS
logP3.87Chemaxon
logS-5ALOGPS
pKa (Strongest Acidic)3.98Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area76.37 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity109.33 m3·mol-1Chemaxon
Polarizability42.76 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0100900000-32e9cf45b676cdbf8434
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002o-0209400000-9d7415251041f99e8245
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-1003900000-eb3a19b7befe3b0923a1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9578100000-7592992fa5f27d92011e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03e9-7097300000-af56dd95fec3b1d23e11
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-06a3b70ff6923f894ae3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-200.07253
predicted
DeepCCS 1.0 (2019)
[M+H]+202.4681
predicted
DeepCCS 1.0 (2019)
[M+Na]+208.4195
predicted
DeepCCS 1.0 (2019)

Drug created at October 17, 2016 21:26 / Updated at February 21, 2021 18:53